Skip to main content
Top
Published in: BMC Urology 1/2014

Open Access 01-12-2014 | Technical advance

Development of an in vitro model to measure bioactivity of botulinum neurotoxin A in rat bladder muscle strips

Authors: Janneke IM van Uhm, Goedele MA Beckers, Willem J van der Laarse, Eric JH Meuleman, Albert A Geldof, Jakko A Nieuwenhuijzen

Published in: BMC Urology | Issue 1/2014

Login to get access

Abstract

Background

Botulinum toxin A (BoNT-A) is a new treatment modality in various causes of bladder dysfunction; like neurogenic detrusor overactivity and overactive bladder. The best technique of administrating BoNT-A in patients is unknown. A validated in vitro model could be used to investigate newer intravesical administration techniques of BoNT-A. In this study, we describe the development and validation of in vitro model to measure inhibitory effects of BoNT-A on bladder strip contractions.

Methods

Rat bladder strips were mounted in organ baths filled with Krebs’ solution. The strips were stimulated chemically (80 mM potassium chloride, 1 μM carbachol) and electrically (Electrical Field Stimulation (EFS) 100 shocks, 50 V, 20 Hz, every 3 minutes). The viability of the strips was measured by carbachol stimulation at the beginning and at the end of the experiments. The strips were incubated in various concentrations of BoNT-A (0.03, 0.2, 0.3 nM). Controls were incubated in Krebs’ solution only. The inhibition of strip contraction induced by EFS was measured. These measurements were statistically analyzed with a log-logistic model representing diffusion.

Results

All strips remained viable during the experiments. Inhibition of strip contraction was observed after incubation with 0.3 nM BoNT-A. The measurements fitted to a log-logistic model describing diffusion of BoNT-A in the bladder strip. The parameters of the log-logistic model representing diffusion were significant for 0.3 nM BoNT-A. Incubation with 0.2 nM BoNT-A showed insignificant results for 2 out of 3 runs. Incubation with 0.03 nM BoNT-A did not result in significant inhibition of strip contractions.

Conclusions

An in vitro model was developed and validated in which the inhibitory effect of low concentrations of BoNT-A on bladder strip contractions can be measured.
Appendix
Available only for authorised users
Literature
1.
go back to reference Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000, 164: 692-697. 10.1016/S0022-5347(05)67283-7.CrossRefPubMed Schurch B, Stohrer M, Kramer G, Schmid DM, Gaul G, Hauri D: Botulinum-A toxin for treating detrusor hyperreflexia in spinal cord injured patients: a new alternative to anticholinergic drugs? Preliminary results. J Urol. 2000, 164: 692-697. 10.1016/S0022-5347(05)67283-7.CrossRefPubMed
2.
go back to reference Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D: Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011, 12: CD005493-CD005493.PubMed Duthie JB, Vincent M, Herbison GP, Wilson DI, Wilson D: Botulinum toxin injections for adults with overactive bladder syndrome. Cochrane Database Syst Rev. 2011, 12: CD005493-CD005493.PubMed
3.
go back to reference Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C, et al: An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2013, 65: 981-990.CrossRefPubMed Mangera A, Apostolidis A, Andersson KE, Dasgupta P, Giannantoni A, Roehrborn C, Novara G, Chapple C, et al: An updated systematic review and statistical comparison of standardised mean outcomes for the use of botulinum toxin in the management of lower urinary tract disorders. Eur Urol. 2013, 65: 981-990.CrossRefPubMed
4.
go back to reference Apostolidis A, Dasgupta P, Fowler CJ: Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006, 49: 644-650. 10.1016/j.eururo.2005.12.010.CrossRefPubMed Apostolidis A, Dasgupta P, Fowler CJ: Proposed mechanism for the efficacy of injected botulinum toxin in the treatment of human detrusor overactivity. Eur Urol. 2006, 49: 644-650. 10.1016/j.eururo.2005.12.010.CrossRefPubMed
5.
go back to reference Coelho A, Cruz F, Cruz CD, Avelino A: Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012, 61: 1178-1184. 10.1016/j.eururo.2012.01.046.CrossRefPubMed Coelho A, Cruz F, Cruz CD, Avelino A: Spread of onabotulinumtoxinA after bladder injection. Experimental study using the distribution of cleaved SNAP-25 as the marker of the toxin action. Eur Urol. 2012, 61: 1178-1184. 10.1016/j.eururo.2012.01.046.CrossRefPubMed
6.
go back to reference Smith CP, Boone TB, De Groat WC, Chancellor MB, Somogyi GT: Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003, 61: 165-171. 10.1016/S0361-9230(03)00114-X.CrossRefPubMed Smith CP, Boone TB, De Groat WC, Chancellor MB, Somogyi GT: Effect of stimulation intensity and botulinum toxin isoform on rat bladder strip contractions. Brain Res Bull. 2003, 61: 165-171. 10.1016/S0361-9230(03)00114-X.CrossRefPubMed
7.
go back to reference Howles S, Curry J, McKay I, Reynard J, Brading AF, Apostolidis A: Lack of effectiveness of botulinum neurotoxin A on isolated detrusor strips and whole bladders from mice and guinea-pigs in vitro. BJU Int. 2009, 104: 1524-1529. 10.1111/j.1464-410X.2009.08619.x.CrossRefPubMed Howles S, Curry J, McKay I, Reynard J, Brading AF, Apostolidis A: Lack of effectiveness of botulinum neurotoxin A on isolated detrusor strips and whole bladders from mice and guinea-pigs in vitro. BJU Int. 2009, 104: 1524-1529. 10.1111/j.1464-410X.2009.08619.x.CrossRefPubMed
8.
go back to reference Takahashi R, Yunoki T, Naito S, Yoshimura N: Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats. J Urol. 2012, 188: 1993-1999. 10.1016/j.juro.2012.07.001.CrossRefPubMed Takahashi R, Yunoki T, Naito S, Yoshimura N: Differential effects of botulinum neurotoxin A on bladder contractile responses to activation of efferent nerves, smooth muscles and afferent nerves in rats. J Urol. 2012, 188: 1993-1999. 10.1016/j.juro.2012.07.001.CrossRefPubMed
9.
go back to reference Longhurst PA, Uvelius B: Pharmacological techniques for the in vitro study of the urinary bladder. J Pharmacol Toxicol Methods. 2001, 45: 91-108. 10.1016/S1056-8719(01)00133-2.CrossRefPubMed Longhurst PA, Uvelius B: Pharmacological techniques for the in vitro study of the urinary bladder. J Pharmacol Toxicol Methods. 2001, 45: 91-108. 10.1016/S1056-8719(01)00133-2.CrossRefPubMed
10.
go back to reference van der Laarse WJ, des Tombe AL, van Beek-Harmsen BJ, Lee-de Groot MB, Jaspers RT: Krogh’s diffusion coefficient for oxygen in isolated Xenopus skeletal muscle fibers and rat myocardial trabeculae at maximum rates of oxygen consumption. J Appl Physiol. 2005, 99: 2173-2180. 10.1152/japplphysiol.00470.2005.CrossRefPubMed van der Laarse WJ, des Tombe AL, van Beek-Harmsen BJ, Lee-de Groot MB, Jaspers RT: Krogh’s diffusion coefficient for oxygen in isolated Xenopus skeletal muscle fibers and rat myocardial trabeculae at maximum rates of oxygen consumption. J Appl Physiol. 2005, 99: 2173-2180. 10.1152/japplphysiol.00470.2005.CrossRefPubMed
11.
go back to reference Hill AV: The Combinations of Haemoglobin with Oxygen and with Carbon Monoxide. I. Biochem J. 1913, 7: 471-480.CrossRefPubMed Hill AV: The Combinations of Haemoglobin with Oxygen and with Carbon Monoxide. I. Biochem J. 1913, 7: 471-480.CrossRefPubMed
12.
go back to reference Kajbafzadeh AM, Ahmadi H, Montaser-Kouhsari L, Sharifi-Rad L, Nejat F, Bazargan-Hejazi S: Intravesical electromotive botulinum toxin type A administration–part II: clinical application. Urology. 2011, 77: 439-445. 10.1016/j.urology.2010.06.003.CrossRefPubMed Kajbafzadeh AM, Ahmadi H, Montaser-Kouhsari L, Sharifi-Rad L, Nejat F, Bazargan-Hejazi S: Intravesical electromotive botulinum toxin type A administration–part II: clinical application. Urology. 2011, 77: 439-445. 10.1016/j.urology.2010.06.003.CrossRefPubMed
13.
go back to reference Kajbafzadeh AM, Montaser-Kouhsari L, Ahmadi H, Sotoudeh M: Intravesical electromotive botulinum toxin type A administration: part I–experimental study. Urology. 2011, 77: 1460-1464. 10.1016/j.urology.2010.09.036.CrossRefPubMed Kajbafzadeh AM, Montaser-Kouhsari L, Ahmadi H, Sotoudeh M: Intravesical electromotive botulinum toxin type A administration: part I–experimental study. Urology. 2011, 77: 1460-1464. 10.1016/j.urology.2010.09.036.CrossRefPubMed
14.
go back to reference Chuang YC, Tyagi P, Huang CC, Yoshimura N, Wu M, Kaufman J, Chancellor MB: Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009, 182: 786-792. 10.1016/j.juro.2009.03.083.CrossRefPubMed Chuang YC, Tyagi P, Huang CC, Yoshimura N, Wu M, Kaufman J, Chancellor MB: Urodynamic and immunohistochemical evaluation of intravesical botulinum toxin A delivery using liposomes. J Urol. 2009, 182: 786-792. 10.1016/j.juro.2009.03.083.CrossRefPubMed
Metadata
Title
Development of an in vitro model to measure bioactivity of botulinum neurotoxin A in rat bladder muscle strips
Authors
Janneke IM van Uhm
Goedele MA Beckers
Willem J van der Laarse
Eric JH Meuleman
Albert A Geldof
Jakko A Nieuwenhuijzen
Publication date
01-12-2014
Publisher
BioMed Central
Published in
BMC Urology / Issue 1/2014
Electronic ISSN: 1471-2490
DOI
https://doi.org/10.1186/1471-2490-14-37

Other articles of this Issue 1/2014

BMC Urology 1/2014 Go to the issue